Ben Durrant

ImmunoPDT is a clinical-stage biotechnology company developing investigational photodynamic immunotherapy programs for early-stage prostate cancer. The company’s platform combines a proprietary oral agent with light-based activation to trigger a targeted, localised therapeutic response, with the aim of addressing an unmet gap between active surveillance and definitive local therapies. ImmunoPDT’s approach is designed to be minimally invasive and compatible with existing clinical workflows. ImmunoPDT is advancing its lead program, Immuno1, through clinical development, with a focus on generating high-quality clinical evidence and building a robust intellectual property position. The company is headquartered in Australia and engages with clinicians, researchers, and strategic partners globally. ImmunoPDT is committed to disciplined, evidence-anchored development and transparent communication appropriate to a regulated, investor-facing environment.

ImmunoPDT is a clinical-stage biotechnology company developing investigational photodynamic immunotherapy programs for early-stage prostate cancer. The company’s platform combines a proprietary oral agent with light-based activation to trigger a targeted, localised therapeutic response, with the aim of addressing an unmet gap between active surveillance and definitive local therapies. ImmunoPDT’s approach is designed to be minimally invasive and compatible with existing clinical workflows. ImmunoPDT is advancing its lead program, Immuno1, through clinical development, with a focus on generating high-quality clinical evidence and building a robust intellectual property position. The company is headquartered in Australia and engages with clinicians, researchers, and strategic partners globally. ImmunoPDT is committed to disciplined, evidence-anchored development and transparent communication appropriate to a regulated, investor-facing environment.